Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Cocrystal Pharma to post earnings of ($0.55) per share for the quarter.
Cocrystal Pharma Price Performance
Shares of COCP stock opened at $1.58 on Tuesday. The stock has a market capitalization of $16.07 million, a PE ratio of -0.85 and a beta of 2.35. Cocrystal Pharma has a 1-year low of $1.35 and a 1-year high of $3.26. The business has a 50-day moving average of $1.85 and a 200 day moving average of $1.94.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Cocrystal Pharma in a report on Wednesday, January 22nd.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Recommended Stories
- Five stocks we like better than Cocrystal Pharma
- ESG Stocks, What Investors Should Know
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Most Volatile Stocks, What Investors Need to Know
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- What is the Shanghai Stock Exchange Composite Index?
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
